Department of Medicine, Division of Renal Medicine, Brigham and Women's Hospital.
Dana-Farber Cancer Institute.
Am J Clin Oncol. 2020 Jan;43(1):14-19. doi: 10.1097/COC.0000000000000618.
Pleurex catheters are a form of palliative therapy for patients, offering relief from symptomatic ascites while also affording greater independence and flexibility; however, aggressive drainage can lead to significant total body sodium losses. We describe the course of patients with "Pleurex desalination," an under-appreciated cause of hypovolemic hyponatremia, highlighting its unique pathophysiology and providing recommendations on how to manage these complex patients.
We included representative patients with "Pleurex desalination" who were evaluated and treated by the renal consult service at Brigham and Women's between 2017 and 2019.
We identified 3 patients who were hospitalized with "Pleurex desalination" and had complete data on serum and urine studies, as well as treatment course. We demonstrate that patients with "Pleurex desalination" were removing up to 1 to 2 L of ascitic fluid a day and were admitted with signs and symptoms of profound hypovolemia and hyponatremia. Patients worsened with administration of diuretics and salt restriction and improved with aggressive fluid resuscitation in the form of hypertonic saline, normal saline, and/or intravenous albumin.
"Pleurex desalination" is an under-recognized cause of hyponatremia; at-risk patients require close observation and periodic resuscitation with intravenous, volume-expanding fluids.
引流导管是一种姑息疗法,可为有症状的腹水患者提供缓解,并提供更大的独立性和灵活性;然而,过度引流会导致大量的总钠丢失。我们描述了“引流导管脱盐”患者的病程,这是低容量性低钠血症的一个未被充分认识的原因,强调了其独特的病理生理学,并就如何管理这些复杂的患者提供了建议。
我们纳入了 2017 年至 2019 年期间在布里格姆妇女医院接受肾脏咨询服务评估和治疗的“引流导管脱盐”代表性患者。
我们确定了 3 名患有“引流导管脱盐”并具有完整血清和尿液研究以及治疗过程数据的住院患者。我们证明,“引流导管脱盐”患者每天可去除多达 1 至 2 升的腹水,并因严重低血容量和低钠血症的症状和体征而入院。患者在给予利尿剂和盐限制后病情恶化,并通过高渗盐水、生理盐水和/或静脉白蛋白进行积极的液体复苏而改善。
“引流导管脱盐”是低钠血症的一个未被充分认识的原因;高危患者需要密切观察,并定期通过静脉补液进行复苏。